EUVIMEDEUVIMED entdecken
Crossref

Suppression of CBP/p300 induces growth inhibition and autophagy of hepatocellular carcinoma cells through regulation of EPHA2 by its super-enhancer acetylation

Lishan Xi, Bodi Zhang, Bei Lan iD

Biochemistry and Cell Biology · 01.01.2026 · 104 · 1-12

DOI: 10.1139/bcb-2025-0377 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biochemistry and Cell Biology, erschienen am 01.01.2026. Verfasst von Lishan Xi und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Tianjin Medical University, Tianjin 300070, China. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Autophagy, Receptor, EphA2. Die Arbeit nennt 45 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

CREB binding protein (CBP) and its homolog E1A binding protein p300 (p300) are crucial lysine acetyltransferases that have been shown to play key roles in various human malignancies. However, the precise functions and regulatory mechanisms of CBP/p300 in hepatocellular carcinoma (HCC) remain to be explored. Herein, we report that the expression levels of CBP and p300 are upregulated in HCC compared to normal tissues, and high CBP expression is associated with poor overall survival based on TCGA data. Combined knockdown of CBP and p300 or treatment with the CBP/p300 histone acetyltransferases (HAT) inhibitor A-485 reduces cell viability and promotes cell death in HCC cell lines. Additionally, inhibition of CBP/p300 activates autophagy, which mediates cell death in HCC cells. Mechanistically, the inhibition of CBP/p300 HAT activity attenuates H3K27ac at Ephrin type-A receptor 2 ( EPHA2) super-enhancer and suppresses the expression of EPHA2. EPHA2 overexpression can partially rescue CBP/p300 HAT inhibition-mediated autophagy and loss of cell viability. These findings reveal a novel epigenetic mechanism of CBP/p300 in HCC and identify the CBP/p300 inhibitor A-485 as a promising therapeutic candidate for HCC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsAutophagyReceptor, EphA2CREB-Binding Proteinp300-CBP Transcription FactorsE1A-Associated p300 ProteinHumansSuper EnhancersAcetylationCell ProliferationCell Line, TumorHeterocyclic Compounds, 4 or More Rings

Stichwörter der Autor:innen

CBP/p300EPHA2autophagycell viabilitysuper-enhancer

Substanzen

Receptor, EphA2EPHA2 protein, humanCREB-Binding ProteinA-485 compoundCREBBP protein, humanp300-CBP Transcription FactorsEP300 protein, humanE1A-Associated p300 ProteinHeterocyclic Compounds, 4 or More Rings

Autor:innen und Institutionen

  • Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Tianjin Medical University, Tianjin 300070, China.

ORCID-Profile: Bei Lan

Zitieren

APA

Xi, L., Zhang, B., & Lan, B. (2026). Suppression of CBP/p300 induces growth inhibition and autophagy of hepatocellular carcinoma cells through regulation of EPHA2 by its super-enhancer acetylation. Biochemistry and Cell Biology, 104, 1-12. https://doi.org/10.1139/bcb-2025-0377

Vancouver

Xi L, Zhang B, Lan B. Suppression of CBP/p300 induces growth inhibition and autophagy of hepatocellular carcinoma cells through regulation of EPHA2 by its super-enhancer acetylation. Biochemistry and Cell Biology. 2026;104:1-12. doi:10.1139/bcb-2025-0377

BibTeX
@article{Xi2026,
  author = {Xi, Lishan and Zhang, Bodi and Lan, Bei},
  title = {Suppression of CBP/p300 induces growth inhibition and autophagy of hepatocellular carcinoma cells through regulation of EPHA2 by its super-enhancer acetylation},
  journal = {Biochemistry and Cell Biology},
  year = {2026},
  volume = {104},
  pages = {1--12},
  doi = {10.1139/bcb-2025-0377}
}
Kostenlos starten →